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                                                         ABSTRAK 
Pengenalan 
Menopaus merupakan satu fasa yang penting dalam kehidupan wanita. Perubahan klinikal yang 
berlaku pada peringkat umur ini bukan sahaja melibatkan struktur vasomotor, genitourinari, 
gangguan tidur, dan perubahan keadaan jiwa, tetapi juga melibatkan struktur mata misalnya 
lapisan air mata, kanta mata, tekanan mata, pengaliran darah dalam mata dan juga retina. Selain 
daripada terapi hormone (HRT), terdapat terapi alternative termasuk pengamalan madu yang 
menunjukkan kesan yang baik dalam merawat simptom menopaus and juga dalam merawat 
penyakit mata dan mengekalkan fungsi struktur mata. 
 
Objektif 
Matlamat kajian ini adalah untuk membandingkan ketebalan makula, ketebalan urat saraf retina 
dan parameter kepala saraf optik di kalangan wanita menopaus yang mengamalkan pengambilan 
produk madu koktail 
 
Kaedah Kajian 
Kajian ini merupakan kajian prospektif terkawal secara rawak yang dikendalikan di Hospital 
Universiti Sains Malaysia antara bulan Mac 2014 dan Julai 2015. Seramai 60 wanita menopaus 
yang memenuhi kriteria pemilihan telah dipilih dan di rawakkan ke dalam 2 kumpulan 
menggunakan teknik rawak sampul surat legap, kumpulan “MADU KOKTAIL” dan kumpulan 
“TANPA MADU”. Paras ketebalan makula dasar, ketebalan urat saraf retina dasar dan parameter 
xiii 
 
kepala saraf optik dasar diambil menggunakan mesin OCT Cirrus HD oleh pegawai terlatih 
tanpa mengetahui kumpulan kajian. Peserta dalam kumpulan “MADU KOKTAIL” diarahkan 
untuk mengambil madu koktail yang dibekalkan untuk tempoh 3 bulan. Peserta perlu mengambil 
sebungkus madu koktail yang mengandungi 20 gram satu hari terus daripada bungkusan tanpa 
melarutkannya. Peserta dalam kumpulan “TANPA MADU” tidak dibekalkan placebo. Selepas 3 
bulan, semua paras ketebalan makula, ketebalan urat saraf retina and parameter kepala saraf 
optic diulangi menggunakan mesin, pegawai and teknik yang sama. Analisa statistik dijalankan 
mengggunakan SPSS versi 22.0 
 
Keputusan 
Seramai 60 peserta telah dipilih (30 peserta dalam setiap kumpulan iaitu kumpulan madu koktail 
and kumpulan tanpa madu. Purata keseluruhan ketebalan makula menunjukkan ketebalan yang 
ketara dengan pengambilan madu koktail di kalangan wanita menopaus 3 bulan selepas rawatan 
(p = 0.002).Terdapat juga perbezaan yang ketara dalam perubahan purata keseluruhan dalam 
ketebalan makula pada 3 bulan selepas rawatan di antara kedua-dua kumpulan (p <0.001). Purata 
keseluruhan ketebalan urat saraf retina menunjukkan ketebalan yang ketara dengan pengambilan 
madu koktail di kalangan wanita menopaus 3 bulan selepas intervensi (p = 0.033). Terdapat juga 
perbezaan yang ketara dalam perubahan purata keseluruhan dalam ketebalan urat saraf retina 
pada 3 bulan selepas rawatan di antara kedua-dua kumpulan (p < 0.001). Tiada perbezaan yang 
ketara dalam parameter paras kepala saraf optik di kalangan wanita menopaus antara kumpulam 
madu koktail dengan dan tanpa pengambilan madu 3 bulan selepas rawatan. Terdapat perbezaan 
yang ketara dalam perubahan purata kawasan lingkaran (p = 0.003), kawasan cawan (p = 0.001) 
xiv 
 
dan nisbah cawan kepada cakera (p < 0.001) pada masa 3 bulan selepas rawatan di antara kedua-
dua kumpulan. 
 
Kesimpulan 
Madu memaparkan kesan positif dalam melindungi ketebalan makula, urat saraf retina dan juga 
parameter kepala saraf optik di kalangan wanita menopaus. 
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                                                           ABSTRACT 
Introduction 
Menopause is an integral part of a woman’s life. The clinical changes that occur during this 
period of life not only involve vasomotor, genitourinary, sleep disturbances and mood changes 
but also involve ocular structures such as tear film, lens, intraocular pressure, ocular blood flow 
and the retina. Apart from hormone replacement therapy (HRT), many other alternative therapies 
including honey showed promising effect in relieving menopausal symptoms, treating ocular 
diseases and maintain ocular functions. 
 
Objective 
To compare mean macular thickness, retinal nerve fiber layer (RNFL) thickness and optic nerve 
head (ONH) parameters with and without honey cocktail supplement in post-menopausal 
women. 
 
Methods 
This is a prospective randomized controlled trial conducted in Hospital Universiti Sains Malaysia 
between March 2014 and July 2015. A total of 60 post-menopausal women who fulfilled the 
selection criterias were selected and randomized into 2 groups using randomized opaque 
envelope technique “HONEY COCKTAIL” and “NO HONEY”. Baseline macular thickness, 
RNFL thickness and ONH parameters were taken using Cirrus HD-OCT machine for both 
groups by blinded trained personnel. Participants in the “HONEY COCKTAIL” group were 
xvi 
 
instructed to take honey cocktail from the honey cocktail sachets provided for a total of 3 months 
duration. The dosing was 1 sachet containing 20 grams per day consumed straight from the 
sachet without dilution. Participant in the “NO HONEY” group were not given any placebo. 
After 3 months, the macular thickness, RNFL thickness and ONH parameters were repeated 
using the same machine, same technique and by the same blinded medical personnel. Statistical 
analysis was performed using SPSS version 22.0. 
 
Results 
A total of 60 participants were recruited (30 participants in each honey cocktail and no honey 
group). The mean global macular thickness was significantly thicker in post-menopausal women 
with honey supplement 3 months post supplement therapy (p = 0.002). There was also a 
significant difference in the mean change of global macular thickness at 3 months post 
supplement therapy between the 2 groups (p < 0.001). The mean global RNFL thickness was 
significantly higher in post-menopausal women with honey supplement 3 months post 
intervention (p = 0.033). There was also a significant difference in the mean change of global 
RNFL thickness at 3 months post supplement therapy between the 2 groups (p < 0.001). There 
were no significant difference in the ONH parameters in post-menopausal women with and 
without honey cocktail supplement 3 months post supplement therapy. There was significant 
difference in the mean change of rim area (p = 0.003), cup area (p = 0.001) and cup-disc-ratio (p 
<0.001) at 3 months post supplement therapy between the 2 groups. 
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Conclusion 
Honey cocktail was shown to be beneficial and protective in improving macular thickness, 
RNFL thickness and ONH parameters in post-menopausal women.  
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                   INTRODUCTION 
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1.1 Introduction 
One of the most important and integral part of a woman’s life is menopause. This typically 
happens after 12 months period of amenorrhea that occurs after the final menstrual period. The 
clinical manifestation of menopause not only involves systems such as vasomotor, genitourinary, 
sleep disturbances and mood changes but also involves the ocular structures such as tear film, 
lens, intraocular pressure, ocular blood flow and retina (Altintas et al., 2004). 
 
Hormone replacement therapy (HRT) has been the mainstay of treatment for decades to aid 
women in coping with changes in their post-menopausal time frame. This therapy has been 
found to be beneficial in protecting ocular structural changes related to menopause as well. In a 
study done among Korean post-menopausal women, it was found that estrogen replacement 
therapy was protective against ocular conditions such as the development of cataract, pterygium, 
and retinal nerve fiber layer defects (Na et al., 2014).  
 
However, in recent years, there’s a paradigm shift towards alternative therapy to help women 
cope with the unpleasant symptoms of menopause and yet lead a normal life. This is due to the 
concerns that HRT could increase the risk of ischemic stroke, cardiovascular diseases and breast 
cancer (Sulaiha et al., 2010). Some of these alternative therapies which are of interest include 
acupuncture, herbal remedies such as evening prime rose oil, ginseng, black cohosh, red clover 
and soy supplement and gingko biloba extract(Geller and Studee, 2005). However, studies done 
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on these remedies are very limited and the results are inconsistent.  Besides this, the effects of 
these remedies on ocular structures are not known and require further elaborative studies. 
 
Lately, there’s an interest in using honey as a modality of treatment for conditions related to 
menopause and several studies have showed promising results (Zaid et al., 2012; Zaid et al., 
2010a). Through these studies, we have learned that honey has a positive effect on estrogen 
sensitive tissues. Ocular structures such as the cornea and retina has been proven to have 
estrogen receptors (Ogueta et al., 1999; Tachibana et al., 2000). Therefore, it can be postulated 
that honey supplement may have an estrogenic effect on the retina and improve retinal 
parameters in post-menopausal women. In addition, honey cocktail which comprise of bee pollen 
and royal jelly apart from honey has been shown to have similar estrogenic effect as honey. 
Hence, it is postulated that the effect on retinal parameters such as macular thickness, retinal 
nerve fiber layer thickness will be similar as honey and when combined together the effect will 
much more enhanced. 
 
In addition, other studies have also demonstrated honey to be a good antioxidant (Bashkaran et 
al., 2011), anti-inflammatory (Bashkaran et al., 2011) and a good rheological agent (Khalil M.I, 
2010). Thus, it is also postulated that these beneficial properties of honey play important role in 
the retina and can improve retinal parameters in post-menopausal women. Moreover, honey is a 
natural substance that readily available, easy to consume and with minimal or no side effects. 
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1.1 Background 
1.2.1 Menopause 
Menopause is a natural progression in a women’s life and in women’s physiology. It is a stage in 
life when a woman stops having her monthly menstruation. It is an integral part of aging and 
marks the end of a woman's reproductive years. Menopause typically occurs in a woman's late 
40s to early 50s. In Malaysia, the average life expectancy in women ranges from 68 years to 75.2 
years and about one third of women’s life is spent in menopause. In a study conducted in 
Singapore found that the mean age of menopause is 49.0 years. This was not significantly 
different between the three ethnic groups (Chinese, Malay and Indians) (Loh et al., 2005). In 
another study looking at the prevalence of menopause in Kelantan, it was found that the mean 
age at menopause was 49.4+/-3.4(SD) (Dhillon et al., 2006). 
 
Natural menopause is the permanent ending of menstruation that is not brought on by any type of 
medical treatment whereas surgical menopause refers to menopause attained in an 
ovariectomized woman. The term climacteric was first coined by Stoppard in 1994 and is 
defined as a phase of transition in a woman’s life whereby their ovarian function and hormonal 
production begin to decline. It can be further divided into pre-menopause, peri-menopause, 
menopause and post-menopause (Stoppard, 1994). 
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The term pre-menopause refers to the entirety of a woman's life from the first to her last regular 
menstrual period (Stoppard, 1994).  Therefore, pre-menopause is best defined as a period of time 
of "normal" reproductive function in a woman leading into the stage of menopause called peri-
menopause. 
 
According to World Health Organization (WHO), peri-menopause is a period of 2-8 year time 
frame preceeding menopause and before complete cessation of the menstrual period. Peri-
menopause usually appears in women from 35-50 years of age. This stage of menopause is 
characterized by hormone fluctuations, which cause the typical menopause like menstrual 
irregularities. The hormonal balance between estrogen, progesterone, follicle stimulating 
hormone (FSH) and lutenizing hormone (LH) in the normal menstrual cycle is altered and these 
hormonal fluctuation results in the symptoms of peri-menopause. During this period of time also, 
FSH and LH levels will start to rise and will be higher. The ovaries at this time will produce less 
estrogen and therefore the estrogen level tends to be lower (Rizk DEE, 1998). The hormonal 
levels of the hypothalamic-pituitary-gonadal axis at peri-menopause stage is shown in Table 1.1.  
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Table 1.1 Hormonal values of the hypothalamic-pituitary-gonadal axis by menopause stage   
                (Navarro et al., 2012) 
           
  
         
During the last 1-2 years of peri-menopause, the drop in estrogen accelerates and peri-
menopause prolongs until to the point when the ovaries stop releasing eggs. Women are still 
having menstrual cycles during peri-menopause, and can get pregnant. 
 
Menopause represents the end stage of a natural transition in a woman's reproductive life. 
Menopause is the point at which estrogen and progesterone production decreases permanently to 
very low levels. In menopause the ovaries stop producing eggs, there’s a permanent cessation of 
a woman’s menstrual cycle and a woman is no longer able to get pregnant naturally. 
 
Post-menopause on the other hand, is a span of life time after the last menstrual period 
(Stoppard, 1994). Post-menopausal period is 12 consecutive months of amenorrhea after the last 
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menstruation. In post-menopause a woman's hormone patterns have changed significantly, 
because the ovaries are no longer producing estrogen or progesterone. Instead of them fat cells 
continue to produce estrogen at around 40 per cent of previous levels. The ovaries have now 
begun to shrink in size but still have quite an important role in post-menopause since some 
hormones continue to be produced there. The transition period from pre-menopause to post-
menopause is shown in Figure 1.1. 
 
 
Figure 1.1 Transition period from pre-menopause to post-menopause in relation to estrogen level 
                 (Adapted from Pauwels et al., 2008) 
 
 
As studies have shown, in post-menopausal women, there’s a drastic change in the hormonal 
status in comparison with normal menstrual cycle. Among all the hormones in the female 
reproductive cycle, estrogen, being a major steroidal female sex hormone produced by the 
ovarian follicles plays a major role and is responsible for the female menstrual cycle and 
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reproductive cycle. It can be classified into three types which include estriol, estradiol and 
estrone. The chemical structures of these hormones are shown in Figure 1.2. 
 
                                 
Figure 1.2 Chemical structure of estradiol, estriol and estrone (Adapted from (Pauwels et al., 
2008) 
 
Among the three subtypes, estradiol is the “active” estrogen produced by the ovaries and is the 
most potent. Estrone on the other hand is considered a weaker form of estrogen. It is typically 
produced by special belly fat cells, and is the major estrogenic form found in naturally-
menopausal women who are not taking HRT. Estriol is a metabolic waste product of estradiol 
metabolism that can still have some effects upon a limited number of estrogen receptors. It is  
8% as potent as estradiol and 14% as potent as estrone. Once estriol is bound to an estrogen 
receptor, it blocks the stronger estradiol from acting there. Thus it is considered to have both 
estrogenic and antiestrogenic actions (Secky et al., 2013). Estradiol is the primary sex hormone 
of childbearing women and is responsible for female characteristic and sexual functioning. The 
main function of estradiol is stimulating growth of breast tissue, maintenance of vaginal blood 
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flow and lubrication, causes lining of the uterus to thicken during the menstrual cycle, keeps 
vaginal lining elastic, and preserving bone density. Other important female hormone includes 
progesterone which aids in the preparation of the lining of the uterus for a fertilized egg and 
helps maintain early pregnancy. Although known as the “male” hormone, testosterone is also 
found in women and is also important to women’s sexual health as it plays a key role in women’s 
estrogen production, contributes to libido and helps to maintain bone and muscle mass.  
 
During menopause, estrogen levels fluctuate and become unpredictable. Eventually, production 
falls to a very low level. In post-menopausal women, estradiol and estrone decline from 62.5% to 
4% of the pre-menopausal level (Vermeulan, 1976). Progesterone production stops during 
menstrual cycles when there is no ovulation and after final menstrual period. Testosterone levels 
on the other hand peak in a woman’s 20s and decline slowly thereafter. By menopause, 
testosterone level is at half of its peak. Ovaries continue to make testosterone even after estrogen 
production stops and testosterone production from adrenal glands also declines with aging but 
continues after menopause. Studies showed a 50% reduction of androgen in menopausal women 
with intact ovaries (Genazzani et al., 1999). The hormonal changes that occur during a women’s 
lifetime and menopause is shown in Figure 1.3A, 1.3B and 1.3C. 
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Figure 1.3 Hormonal level throughout a woman’s life (A), hormonal fluctuations during 
                 menopause (B) and female testosterone decline with age (C) (Adapted from 
                 Deuter et al., 2014-2015) 
 
 
A 
C 
B
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1.2.2 Effects of Menopause 
1.2.2.1 Systemic Effects 
During the transitional period of menopause, women may experience vasomotor symptoms such 
as hot flushes, night sweats and or cold flashes, insomnia, emotional changes such as irritability, 
mood swings, and mild depression. Apart from this, patients also experience uro-genital 
symptoms such as urinary frequency, vaginal dryness and dyspareunia. In a study conducted in 
Kelantan looking at prevalence of menopausal symptoms in women found that night sweats 
(53%), headache (49.4%) and hot flushes (44.8%) were the typical vasomotor symptoms, 
whereas mood swings (51%), sleep problems (45.1%), loneliness (41.1%), anxiety (39.8%) and 
crying spells (33.4%) were the main psychological symptoms. Uro-genital symptoms such as 
vaginal discomfort (45.7%), occasional stress incontinence (40%), weak bladder control (24%) 
and urinary tract infection (19.3%) were also reported. Some patients had atypical symptoms and 
the prevalence of atypical symptoms was as follows: tiredness (79.1%), reduced level of 
concentration (77.5%), musculo-skeletal aches (70.6%) and backache (67.7%) (Dhillon et al., 
2006).  
 
The long term health risks associated with menopause include osteoporosis, coronary artery 
disease and decline in cognitive function. Estrogen plays an important role in preserving bone 
mass. Estradiol especially acts directly on osteoclast by reducing the rate of bone resorption 
(Steinweg, 2002). Many studies done showed that post-menopausal women had lower bone 
mineral density and the decrease in estradiol directly contributes to this. Generally, women lose 
an average of 25% of their bone mass from the time of menopause to age 60. In a study looking 
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at factors affecting bone loss in menopausal women without hormone replacement therapy, it 
was found that, in women under 5 years post-menopausal at baseline, bone loss rate was 
significantly lower than in peri-menopausal women. In women over 5 years post-menopausal at 
baseline, bone loss rate was significantly further decreased only at lumbar spine (Sirola et al., 
2003). Over time, this loss of bone can lead to bone fractures. In addition to this, post-
menopausal state is also associated with high incidence of cardiovascular disease. This is due to 
the emergence of metabolic syndromes which include increase in central and intra-abdominal 
body fat, a change toward more atherogenic lipid profile, with increased low density lipoprotein 
particles and increased insulin resistance (Knopp, 2002). 
 
In other studies looking at the correlation between osteoporosis, arterial stiffness and 
atherosclerosis, it was found that women with osteoporosis had significantly higher arterial 
stiffness and higher arterial stiffness was further associated with the presence of atherosclerosis 
and this provided initial data suggesting that women with osteoporosis may have a higher risk of 
developing coronary atherosclerosis (Seo et al., 2009).  
 
Apart from this, it is also suggested that decline in estrogen around menopause are associated 
with deterioration in cognitive function as well as increased risk of depressive symptoms and 
depressive disorder (Weber et al., 2014). Cognitive function comprises various components but 
the most important aspect that is affected by estrogen decline is verbal learning and memory.  
Clinically, the protective effects of estrogen specifically target the cognitive domains that are the 
most vulnerable to aging in both female rats (Markowska and Savonenko, 2002) and women 
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(Sherwin, 1988). This is due to a decline in estrogen which is largely concentrated at 
hypothalamus, amygdala and hippocampus in menopause (Shughrue and Merchenthaler, 2000). 
Post-menopausal women performed significantly worse than pre- and peri-menopausal women 
on delayed verbal memory tasks, and significantly worse than peri-menopausal women on 
phonemic verbal fluency tasks. Peri-and post-menopausal women were at significantly increased 
risk of depression, as measured by standard symptom inventories and structured clinical 
interviews, than pre-menopausal women (Weber et al., 2014). Therefore, menopausal transition 
is a time of increased vulnerability to cognitive deterioration and increased risk of depressive 
symptoms and depressive disorders. 
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1.2.2.2 Ocular Effects 
The incidence of eye manifestations not only increases with age but there exist a gender base 
difference as well. This is most likely due to the presence of sex steroid hormone receptors in the 
ocular tissues. There’s a strong correlation between estrogen and changes in ocular tissue and 
these changes are more prevalent in the post-menopausal period due to the decline in estrogen.  
 
Dry eye is more common in females and studies have established that androgen controls the 
various biochemical and physiological aspects of the lacrimal apparatus and this hormone is 
generally deficient in females (Sharma and Hindman, 2014). Since women have lower levels of 
androgens compared to the levels in men and further age-related decreases in androgen levels 
may diminish the androgen levels below the critical amount needed for optimum eye health. 
Along with lower androgen levels, post-menopausal women develop lower levels of estrogen 
that is known to stimulate meibomian glands and help regulate ocular surface homeostasis. 
Therefore, a combination of androgen and estrogen deficiency lead to inadequate lacrimal gland 
secretion with superimposed tear-film instability in older women and higher risk of developing 
dry eye (Sriprasert et al., 2015). This observations have been further strengthened by the 
increased association of dry eye during pregnancy and lactation (Sullivan, 2004). Apart from 
this, the conjunctival epithelium seems to show cyclic variations during menstruation and 
menopause. Even the maturity of the conjunctival tissue strongly correlates with the levels of 
estrogen (Wagner et al., 2008).  
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Besides this, the incidence of cataract is much higher in post-menopausal females as compared to 
males of similar age groups and it appears that sex hormones have a significant role in 
prevention of cataract formation in post-menopausal women as observed by one large study. The 
protective action of estrogen is most likely to maintain the ionic composition and hydration 
status in the lens and thus preventing cataract formation (Gupta et al., 2005; Leske et al., 2004).  
 
Post-menopausal women have lower contrast sensitivity detection and elevated intraocular 
pressure (IOP) compared to pre-menopausal women (Siesky et al., 2008). In another study 
conducted in South India found that post-menopausal women had higher IOP that could be 
ascribed to alternating levels of oestrogen and progesterone after menopause, which could act by 
altering any/several components of the IOP regulating mechanisms (Panchami et al., 2013). 
Central corneal thickness also was significantly decreased in post-menopausal women compared 
to pre-menopausal women (Keskin et al., 2009). 
 
There’s also evidence to suggest a relationship between estrogen and retinal disorders. Through 
different known and unknown mechanisms, estrogen exerts a protective role in preventing retinal 
changes by various genomic and non-genomic effects (Evans et al., 1998). This estrogenic effect 
on the retina is possible due to the presence of estrogen receptors in the retina. 
 
In recent years, studies done in rats, bovine and human have demonstrated the presence of 
estrogen receptor in the retina (Kobayashi et al., 1998; L. Alexandra Wickham, 2000; Munaut et 
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al., 2001; Ogueta et al., 1999). Based on the study done by Munaut et al. (2001), 2 types of 
estrogen receptor were identified in the human retina which were estrogen receptor alpha (ERα) 
and estrogen receptor beta (ERβ). Analysis using immune chemical localisation, western blot and 
rapid time polymerase chain reaction (RT-PCR) were done in neural retina, retinal pigment 
epithelium and choroid layer to demonstrate the presence of these receptors. The study 
demonstrated the presence of ERα and ERβ in the neural retina and retinal pigment epithelium 
(RPE)-choroid complex. Expression of ERβ was more constant and evenly distributed in the 
retina, mainly observed in the ganglion cell layer and choroid while expression of ERα was 
unequally distributed between the retina, especially the ganglion cell layer and the RPE-choroid 
complex. Distribution of estrogen receptor in the retinal layers and the distribution of estrogen 
receptor messenger ribonucleic acid (mRNA) in the centre and periphery of the retina is shown 
in Figure 5.1 and 5.2 accordingly.  
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Figure 1.4 Distribution of estrogen receptor in the retinal layers  
                  (Adapted from Munnaut et al., 2001) 
 
        
 
Figure 1.5 Distribution of estrogen receptor mRNA in the centre and the periphery of the retina  
                  (Adapted from Munnaut et al., 2001) 
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In another study done  to assess the influence of estrus cycle on the retinal structure and function 
between aging male and female rats, it was discovered that the electro-retinography (ERG) 
amplitudes were larger in pre-menopausal rats compared to menopausal female rats and were 
also larger than those obtained from age-matched male rats. In contrast, following menopause, 
the ERG responses in female rats declined dramatically compared to age-matched male rats. 
These findings suggest a beneficial effect of the estrus cycle and its related fluctuating hormonal 
changes, especially estrogen upon the retinal function. This may further explain the higher 
prevalence of age-related retinal degeneration in women after menopause (Chaychi et al., 2015). 
Increased incidence of macular degeneration in post-menopausal women due to deficiency of 
estrogen was also observed by the Eye Disease Case–Control Study Group (Evans et al., 1998). 
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1.2.2.2.1 Macular Thickness 
Macular is a very important structure in the human eye and is the most sensitive part of the 
retina. Disease which affects the macula causes visual disruption and affects the quality of life. 
The most common form of macular disease is age related macular degeneration (AMD). It is the 
leading cause of visual loss and blindness among older adults. The prevalence of AMD in the 
United States is 1.75 million and is expected to increase to 3 million by 2020 (Mangione et al., 
1999). This disease is associated with many factors such as aging, smoking, and genetics and is 
more common among female patients especially after the age of 65 and the incidence increases 
with age in females. In AMD there is deposition of lipofuscin at the Bruch membrane, further 
causing thinning and atrophy of retinal pigment epithelial cells. 
 
The researchers suggested that oxidative stress plays an important role in the degeneration of the 
retinal epithelium. In women, the antioxidant properties in estrogen may have a protective role 
against oxidative stress on retina and thus helps promote the survival of the retinal epithelium. In 
post-menopausal women, the antioxidant level is low due to decrease in estrogen and other 
related factors and the reduction of antioxidant increases the oxidative stress on the retina and 
therefore makes these women more prone to AMD.  
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Based on several studies, endogenous estrogen exposure is associated with the risk of AMD. The 
Aravind Comprehensive Eye Survey showed age at menarche ≥14 years, is a risk factor for 
overall AMD (OR, 2.3) (Nirmalan et al., 2004), and the Rotterdam Study showed an increased 
risk of AMD in those who experienced early menopause following oophorectomy (OR, 3.8) 
(Tomany et al., 2004). The Blue Mountain Eye Study reported that a long reproductive period 
was associated with a decreased prevalence of early AMD (Smith et al., 1997). These findings 
provide further support for the notion that a shorter duration of estrogen exposure may increase 
the risk of AMD. Apart from this, researchers have also shown that menopausal females not on 
HRT have a higher risk to develop AMD compared to menopausal females on HRT (Klein, 
2000). Hence, female reproductive hormone especially estrogen may have protective effect 
against AMD. 
 
Apart from AMD, other macular diseases such as idiopathic macular hole which accounts for 
0.3% of macular disease has been shown to have a higher prevalence in females with female: 
male ratio of 3:1 (Morgan and Schatz, 1986). However the underlying cause for this difference is 
unknown.  
 
Several studies done showed that there is a difference in macular thickness between males and 
females (Adhi et al., 2012; Murthy et al., 2015; Song et al., 2010; Wexler et al., 2010; Wong et 
al., 2005). This thickness appears to be more in males. The difference in macular thickness 
varies with age and is more distinct in older men and women. Only a few studies did not find 
gender differences in macular thickness (Chan et al., 2006; Grover et al., 2009; Sull et al., 2010). 
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Therefore based on these findings, it is postulate that the disparity of macular thickness between 
males and females can be due to influence of sex hormones.  
 
So far, there is very limited data on the normative data of macular thickness in post-menopausal 
women compared to reproductive age group women to assess whether there is an effect of 
female reproductive hormone on macula thickness. Based on a population based study carried 
out by Atas et al. (2014) in evaluating macular thickness, RNFL and choroid thickness in post-
menopausal women and reproductive age group, they found that after adjusting for age there was 
significant thinning of the central subfield, and temporal inner macula in post-menopausal 
women compared to reproductive age group women. This shows that female reproductive 
hormone do influence the macula thickness. 
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1.2.2.2.2 Retinal Nerve Fiber Layer Thickness  
Retinal nerve fiber layer (RNFL) is the innermost layer of the retina which consists of axons and 
ganglion cells that follow a characteristic pattern towards the optic disc. The fibers exit the eye as 
optic nerve. It is a very important structure in the human eye. There is emerging evidence that 
estrogen metabolism has a vital role in the pathogenesis of primary open-angle glaucoma 
(POAG). In a study done showed that among women ≥ 65 years, early age of menopause (≤ 45 
years) was associated with an increased risk of POAG (Hulsman et al., 2001), whereas later age 
of onset of menopause (≥ 54 years) was associated with a decreased risk of POAG (Pasquale et 
al., 2007). Researchers found that retinal ganglion cells express estrogen receptors (Munaut et 
al., 2001), and estrogen has beneficial effects in animal models of neurodegenerative disorders, 
including glaucoma (Carroll et al., 2010; Morissette et al., 2008). Therefore, in menopause, the 
decline in estrogen level removes the protective effect of estrogen on retinal ganglion cells, 
causes RNFL thinning and increases the risk of patients to POAG. 
 
Besides this, retinal ganglion cells are vulnerable to oxidative stress which generates reactive 
oxygen species. This leads to tissue hypoxia and further degeneration of the retinal ganglion cells 
(Munemasa and Kitaoka, 2012). Estrogen which has anti-oxidant properties removes this 
unwanted effect and protects the retinal ganglion cells and prevents RNFL thinning (Pasquale et 
al., 2007). 
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In another study comparing the sex specific differences in RNFL thinning following acute optic 
neuritis, it was found that men had worse RNFL thinning that women after optic neuritis. On this 
aspect, estrogen has been shown to increase retinal blood flow and protect the RNFL in animal 
and clinical models of optic nerve injury (Deschenes et al., 2010). In an experimental model of 
Leber hereditary optic neuropathy, administration of 17β-estradiol activated mitochondrial 
biogenesis and improved energetic competence, showing the protective effects of estrogen that 
may explain the higher prevalence of Leber hereditary optic neuropathy in men relative to 
women (Giordano et al., 2011). 
 
Based on the assessment of RNFL thickness between gender, various studies done in different 
countries showed no obvious difference in RNFL thickness between the gender (Alasil et al., 
2013; Budenz et al., 2007; Mansoori et al., 2012). However, one study done among Chinese 
population showed there was significant difference in the RNFL in the nasal quadrant between 
males and females and the thickness was higher in males (Qu et al., 2014).  
 
So far, there is very limited data on the normative data of RNFL thickness in post-menopausal 
women compared to reproductive age group women to assess whether there is an effect of 
female reproductive hormone on RNFL thickness. In Atas et al. (2014) study evaluating RNFL 
thickness between post-menopausal women and reproductive age group women, there was no 
significant difference found in the peripapillary RNFL thickness parameters between post-
menopausal women and control group. 
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1.2.2.2.3 Optic Nerve Head (ONH) Parameters 
Optic nerve head (ONH) is a small blind spot on the surface of the retina, located about 3 mm to 
the nasal side of the macula. It is the point where the retinal nerve fibers leave the eye and 
become part of the optic nerve. It is the only part of the retina that is insensitive to light. At the 
center the porus opticus marks the point of entrance of the central artery and vein of the retina. 
Evidence supports the hypothesis that estrogen deficiency is involved in the patho-physiology of 
optic nerve aging and glaucomatous neurodegeneration through several mechanisms (Vajaranant 
and Pasquale, 2012). 
 
In relation to the mechanical theory, estrogens may regulate IOP by influencing the aqueous 
production and outflow systems through receptors in the ciliary epithelium (Altintas et al., 2004; 
Ogueta et al., 1999). In menopause, the decline in estrogen causes this regulation to be affected. 
With regards to the vascular theory, estradiol regulates smooth muscle tone and vascular 
resistance and augments the activity of endothelial-based nitric oxide synthase (NOS3) (Kang et 
al., 2010). Specifically, estradiol may influence perfusion of the optic nerve, retinal ganglion 
cells, and their supporting structures. This effect has been demonstrated in animal models and 
clinical studies (Deschenes et al., 2010; Harris et al., 2000). A 22–45% increase in perfusion to 
the retina was reported in ovariectomized rats treated with estradiol compared to control 
ovariectomized rats treated with vehicle (Deschenes et al., 2010). In humans, aging and age-
related decreases in female sex hormones negatively affect ocular blood flow. In addition to 
clinical evidence and animal models, epidemiologic studies have also demonstrated an 
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association between decreased estrogen exposure and the risk for developing glaucoma later in 
life (Hulsman et al., 2001; Nirmalan et al., 2004). 
 
Several studies done on ONH parameters showed there exists difference in ONH parameters 
between males and females (Hermann et al., 2004; Ramrattan et al., 1999; Tariq et al., 2012; 
Zhang et al., 2014). A study done among healthy adults in Kelantan also showed variation in 
ONH parameters between males and females (Jusoh et al., 2011). These differences suggest a 
possible role of reproductive hormonal influence on ONH parameters. However, till date, there’s 
no normative data regarding ONH measurement in post-menopausal women 
 
 
 
 
 
 
 
 
 
 
